Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-648-7 | CAS number: 123-75-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Comparable to guideline study with acceptable restrictions (used animals, limited documentation).
Data source
Referenceopen allclose all
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 959
- Report date:
- 1959
- Reference Type:
- secondary source
- Title:
- Unnamed
- Year:
- 1 959
- Report date:
- 1977
- Reference Type:
- review article or handbook
- Title:
- Gesundheitsschaedliche Arbeitsstoffe, Toxikologisch-arbeitsmedizinische Begruendung von MAK-Werten (Maximale Arbeitsplatz-Konzentrationen), Pyrrolidin
- Author:
- MAK-Kommission
- Year:
- 1 977
- Bibliographic source:
- published in: VCH Weinheim, Germany, 20. Lieferung 1994
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- yes
- Remarks:
- used animals
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- Pyrrolidine
- EC Number:
- 204-648-7
- EC Name:
- Pyrrolidine
- Cas Number:
- 123-75-1
- Molecular formula:
- C4H9N
- IUPAC Name:
- pyrrolidine
- Details on test material:
- - Name of test material (as cited in study report): Pyrrolidin
- Physical state: liquid
- Analytical purity: 95 - 97 %
Constituent 1
Test animals
- Species:
- rat
- Strain:
- not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: breeder
- Weight at study initiation: females: 152 - 230 g; males: 154 - 252 g
ENVIRONMENTAL CONDITIONS
- No data
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: The doses were applied as 1 % or 10 % preparations of the test substance in aqua dest.
- Justification for choice of vehicle: soluble in water
MAXIMUM DOSE VOLUME APPLIED: 20 mL/kg - Doses:
- 200, 400, 500, 640 and 1600 µL/kg bw (corresponding to approx. 172, 344, 430, 550, 1374 mg/kg bw; calculation based on density of 0.859 g/cm³)
- No. of animals per sex per dose:
- 172 mg/kg bw: 3 females, 2 males; 344 mg/kg bw: 5 females; 430 mg/kg bw: 5 females and 5 males; 550 mg/kg bw: 5 females; 1374 mg/kg bw: 3 females.
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 7 days
- Frequency of observations and weighing: Body weight was determined before the beginning of the study for dose calculation. Observation of clinical signs was determined several times on the day of administration and once daily afterwards with the exception of weekends and on holidays.
- Necropsy of survivors performed: yes, at 344 mg/kg bw and higher concentrations. No necropsy was done at 172 mg/kg bw.
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 430 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: The original value 0.5 mL/kg was converted to mg/kg body weight using the density of 0.859 g/cm³
- Mortality:
- Results are given as dead animals/total number of animals:
172 mg/kg bw: females: 0/3; males: 0/2
344 mg/kg bw: females: 1/5 (one day after treatment).
430 mg/kg bw: females: 0/5; males: 4/5 (one animal on the day of treatment, one animal on day 2, 3 and 6 after treatment, respectively)
550 mg/kg bw: females: 5/5 (3 within 10 min after treatment; one on day 4 and 5 after treatment, respectively)
1374 mg/kg bw: females: 3/3 (on the day of treatment) - Clinical signs:
- 172 and 322 mg/kg bw: females: accelerated respiration after treatment; one day after treatment no abnormality detected.
430, 550, 1374 mg/kg bw: after treatment: hindered respiration; latero-abdominal position; apathy; flaccid tonus. The next day at the nose and eyes of the animals bloody crust formation. No food intake after treatment. Surviving animals show food intake 4 days after treatment. - Body weight:
- No data about body weight gain.
- Gross pathology:
- Deceased animals:
344 mg/kg bw: females: no abnormality detected.
430 mg/kg bw: females: chemical burns to the stomach and duodenum; gastro-intestinal vessels strongly injected; focal pneumonia; hemothorax, fragile, thickened stomach wall, partly conjoined with the peritoneum.
550 mg/kg bw: no abnormality detected.
1374 mg/kg bw: gastro-intestinal chemical burns; vessels strongly injected.
Sacrifized animals:
430 mg/kg bw: hydrothorax; extensive adhesions between stomach, liver and spleen; gastritis, gastric wall thickened.
344 mg/kg bw: gastritis
Any other information on results incl. tables
Table1. Acute oral toxicity.
Dose [mg/kg bw] |
Mortality |
||
|
N* |
% |
Time of death |
Males |
|
|
|
172 |
0/2 |
0 |
- |
344 |
n.d. |
- |
- |
430 |
4/5 |
80 |
Day 1, 2, 3, and 6, one animal each day. |
550 |
n.d. |
- |
|
1374 |
n.d. |
- |
|
Females |
|
|
|
172 |
0/3 |
0 |
- |
344 |
1/5 |
20 |
Day 2 |
430 |
0/5 |
0 |
- |
550 |
5/5 |
100 |
3 within 10 min, on day 4 and 5, one animal each |
1374 |
3/3 |
100 |
Day 1 |
N= Number of animals/ number of animals used; n.d.: not determined.
Applicant's summary and conclusion
- Conclusions:
- Under the conditions of this study the LD50 for male and female rats after oral application was determined to be 430 mg/kg bw.
- Executive summary:
In principle, the methods described in OECD Guideline 401 were used in this study. Young adult laboratory rats were purchased from breeder. Several groups of rats were treated simultaneously by gavage with preparations of the test substance in water. The concentrations of these preparations were used to achieve comparable volumes per kg body weight. Group-wise documentation of clinical signs was performed over the 7-day study period. Body weight was determined before the start of the study only, as it was needed for determination of dose.
The following clinical signs were observed: accelerated respiration, hindered respiration, latero-abdominal position, apathy, flaccid tonus, bloody crust formation at noses and eyes, and no food intake for several days after treatment.
At necropsy, the following observations were made in deceased animals: chemical burns to the stomach and duodenum, strongly injected gastro-intestinal vessels, focal pneumonia, hemothorax, and fragile, thickened stomach wall, partly conjoined with the peritoneum.
The LD50 for male and female rats after oral application was determined to be 430 mg/kg bw.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
